Payment overview · 2025
General Payments
$788.56
32 reported records · 13 companies
Healthcare provider profile · identity verified
Sadaf Bazargan, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LUTZ, FL · NPI 1265461941
Verified facts
What the public records show
CMS Open Payments records show Sadaf Bazargan, MD received $788.56 in general payments during 2025 across 32 reported records.
PFIZER INC. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $299.97 | 38.0% | 14 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $91.97 | 11.7% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.73 | 10.2% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $70.79 | 9.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.04 | 6.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.87 | 4.0% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $29.85 | 3.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $27.46 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.64 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.82 | 3.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $21.72 | 2.8% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $15.49 | 2.0% | 1 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $14.21 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $788.56 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $299.97 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $211.78 | 13 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $91.97 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $70.79 | 2 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $62.63 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $31.87 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $27.46 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
135 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 1638 | 160 |
| Morphine Sulfate Er | Morphine Sulfate | 796 | 87 |
| Gabapentin | Gabapentin | 701 | 97 |
| Tizanidine Hcl | Tizanidine Hcl | 481 | 66 |
| Pregabalin | Pregabalin | 475 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 377 | 52 |
| Ibuprofen | Ibuprofen | 313 | 52 |
| Celecoxib | Celecoxib | 303 | 55 |
| Methadone Hcl | Methadone Hcl | 298 | 33 |
| Hydromorphone Hcl | Hydromorphone Hcl | 272 | 35 |
| Alprazolam | Alprazolam | 209 | 29 |
| Xtampza Er | Oxycodone Myristate | 205 | 22 |
| Oxycontin | Oxycodone Hcl | 204 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 197 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 168 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 21 |
| Methocarbamol | Methocarbamol | 149 | 26 |
| Mupirocin | Mupirocin | 146 | 34 |
| Baclofen | Baclofen | 137 | 20 |
| Diazepam | Diazepam | 137 | 21 |
| Lorazepam | Lorazepam | 137 | 17 |
| Linzess | Linaclotide | 135 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 27 |
| Promethazine Hcl | Promethazine Hcl | 119 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 21 |
| Clonazepam | Clonazepam | 116 | 13 |
| Omeprazole | Omeprazole | 115 | 16 |
| Ondansetron Odt | Ondansetron | 109 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 11 |
| Lamotrigine | Lamotrigine | 97 | 15 |
| Naloxone Hcl | Naloxone Hcl | 96 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 18 |
| Sertraline Hcl | Sertraline Hcl | 92 | 14 |
| Carisoprodol | Carisoprodol | 82 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 12 |
| Lisinopril | Lisinopril | 80 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 74 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 70 | 12 |
| Buspirone Hcl | Buspirone Hcl | 69 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 68 | 12 |
| Prednisone | Prednisone | 66 | 12 |
| Fentanyl | Fentanyl | 65 | suppressed |
| Naproxen | Naproxen | 64 | 11 |
| Topiramate | Topiramate | 63 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 58 | suppressed |
| Mirtazapine | Mirtazapine | 57 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 57 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 57 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | suppressed |
| Temazepam | Temazepam | 51 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | suppressed |
| Famotidine | Famotidine | 47 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 46 | suppressed |
| Ibu | Ibuprofen | 46 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Ubrelvy | Ubrogepant | 42 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 40 | suppressed |
| Lidocaine | Lidocaine | 40 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Losartan Potassium | Losartan Potassium | 32 | suppressed |
| Dexamethasone | Dexamethasone | 29 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 29 | suppressed |
| Furosemide | Furosemide | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 11 |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Dronabinol | Dronabinol | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Botox | Onabotulinumtoxina | 14 | suppressed |
| Etodolac Er | Etodolac | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Roxicodone | Oxycodone Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $788.56 · 32 records | PFIZER INC. | BOTOX, Belbuca, General - Pain Management, KESIMPTA, KEVEYIS, NALOCET, NUPLAZID, NURTEC ODT, Ocrevus Zunovo, PROLATE, QULIPTA, ROXYBOND, Symbravo, TANLOR, UBRELVY, VYALEV, WAKIX, XTAMPZA, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error